Calcitriol for postmenopausal osteoporosis

J. C. Gallagher; B. L. Riggs

doi:10.7326/0003-4819-111-7-621_1

Calcitriol for postmenopausal osteoporosis

J. C. Gallagher, B. L. Riggs

Department of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

Calcitriol has not been approved for the treatment of osteoporosis by the Food and Drug Administration. We do not claim that efficacy and safety have been demonstrated, but only that the findings are unclear enough to warrant continued investigation. For example, a recent two center, place-controlled study found that 3 years of treatment with calcitriol of women with postmenopausal osteoporosis resulted in a highly significant 65% reduction of vertebral fracture rate.

Original language	English (US)
Number of pages	1
Journal	Annals of internal medicine
Volume	111
Issue number	7
DOIs	https://doi.org/10.7326/0003-4819-111-7-621_1
State	Published - Jan 1 1989

All Science Journal Classification (ASJC) codes

Internal Medicine

Access to Document

10.7326/0003-4819-111-7-621_1

Cite this

@article{f56804a4a46646e2a1aca75bc1a2c4e4,

title = "Calcitriol for postmenopausal osteoporosis",

abstract = "Calcitriol has not been approved for the treatment of osteoporosis by the Food and Drug Administration. We do not claim that efficacy and safety have been demonstrated, but only that the findings are unclear enough to warrant continued investigation. For example, a recent two center, place-controlled study found that 3 years of treatment with calcitriol of women with postmenopausal osteoporosis resulted in a highly significant 65% reduction of vertebral fracture rate.",

author = "Gallagher, {J. C.} and Riggs, {B. L.}",

year = "1989",

month = jan,

day = "1",

doi = "10.7326/0003-4819-111-7-621_1",

language = "English (US)",

volume = "111",

journal = "Annals of Internal Medicine",

issn = "0003-4819",

publisher = "American College of Physicians",

number = "7",

}

TY - JOUR

T1 - Calcitriol for postmenopausal osteoporosis

AU - Gallagher, J. C.

AU - Riggs, B. L.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Calcitriol has not been approved for the treatment of osteoporosis by the Food and Drug Administration. We do not claim that efficacy and safety have been demonstrated, but only that the findings are unclear enough to warrant continued investigation. For example, a recent two center, place-controlled study found that 3 years of treatment with calcitriol of women with postmenopausal osteoporosis resulted in a highly significant 65% reduction of vertebral fracture rate.

AB - Calcitriol has not been approved for the treatment of osteoporosis by the Food and Drug Administration. We do not claim that efficacy and safety have been demonstrated, but only that the findings are unclear enough to warrant continued investigation. For example, a recent two center, place-controlled study found that 3 years of treatment with calcitriol of women with postmenopausal osteoporosis resulted in a highly significant 65% reduction of vertebral fracture rate.

UR - http://www.scopus.com/inward/record.url?scp=0024394159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024394159&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-111-7-621_1

DO - 10.7326/0003-4819-111-7-621_1

M3 - Comment/debate

C2 - 2604778

AN - SCOPUS:0024394159

SN - 0003-4819

VL - 111

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

IS - 7

ER -

Calcitriol for postmenopausal osteoporosis

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this